PMID- 27729774
OWN - NLM
STAT- MEDLINE
DCOM- 20170517
LR  - 20240326
IS  - 1177-8881 (Electronic)
IS  - 1177-8881 (Linking)
VI  - 10
DP  - 2016
TI  - Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: 
      a meta-analysis.
PG  - 3153-3161
AB  - PURPOSE: Anti-programmed cell death receptor-1 (PD-1) antibodies have 
      demonstrated antitumor activity in many cancer entities. Hepatic adverse events 
      (AEs) are one of its major side effects, but the overall risks have not been 
      systematically evaluated. Thus, we conducted this meta-analysis to investigate 
      the overall incidence and risk of developing hepatic AEs in cancer patients 
      treated with PD-1 inhibitors. METHODS: PubMed, Embase, and oncology conference 
      proceedings were searched for relevant studies. Eligible studies were randomized 
      controlled trials of cancer patients treated with PD-1 inhibitors with adequate 
      data on hepatic AEs. RESULTS: A total of nine randomized controlled trials with a 
      variety of solid tumors were eligible for the meta-analysis. The use of PD-1 
      inhibitors significantly increased the risk of developing all-grade hepatic AEs 
      but not for high-grade hepatic AEs in comparison with chemotherapy or everolimus 
      control. Additionally, the risk of all-grade and high-grade hepatic AEs with a 
      nivolumab/ipilimumab combination was substantially higher than ipilimumab. No 
      significant differences in the risk of all-grade and high-grade hepatic AEs were 
      found between PD-1 inhibitors monotherapy and ipilimumab. CONCLUSION: While the 
      use of PD-1 inhibitors is associated with an increased risk of developing hepatic 
      AEs in cancer patients, this is primarily for lower grade events.
FAU - Zhang, Xi
AU  - Zhang X
AD  - Department of Radiation Oncology.
FAU - Ran, Yuge
AU  - Ran Y
AD  - Department of Radiation Oncology.
FAU - Wang, Kunjie
AU  - Wang K
AD  - Department of Medical Oncology.
FAU - Zhu, Yuanxue
AU  - Zhu Y
AD  - Department of Medical Oncology.
FAU - Li, Jinghua
AU  - Li J
AD  - Department of Hepatobiliary Surgery, Affiliated Hospital of Hebei University, 
      Baoding, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20160928
PL  - New Zealand
TA  - Drug Des Devel Ther
JT  - Drug design, development and therapy
JID - 101475745
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Ipilimumab)
RN  - 9HW64Q8G6G (Everolimus)
SB  - IM
MH  - Antibodies, Monoclonal/*pharmacology
MH  - Antineoplastic Agents/*therapeutic use
MH  - Apoptosis/*drug effects
MH  - Everolimus/*pharmacology
MH  - Hepatitis/diet therapy/*drug therapy
MH  - Humans
MH  - Incidence
MH  - Ipilimumab
MH  - Neoplasms/*drug therapy
MH  - Network Meta-Analysis
MH  - Risk
PMC - PMC5047728
OTO - NOTNLM
OT  - PD-1 inhibitors
OT  - cancer
OT  - hepatic toxicities
OT  - meta-analysis
EDAT- 2016/10/13 06:00
MHDA- 2017/05/18 06:00
PMCR- 2016/09/28
CRDT- 2016/10/13 06:00
PHST- 2016/10/13 06:00 [entrez]
PHST- 2016/10/13 06:00 [pubmed]
PHST- 2017/05/18 06:00 [medline]
PHST- 2016/09/28 00:00 [pmc-release]
AID - dddt-10-3153 [pii]
AID - 10.2147/DDDT.S115493 [doi]
PST - epublish
SO  - Drug Des Devel Ther. 2016 Sep 28;10:3153-3161. doi: 10.2147/DDDT.S115493. 
      eCollection 2016.